Log in

NASDAQ:SBBP - Strongbridge Biopharma Stock Price, Forecast & News

$2.74
+0.22 (+8.73 %)
(As of 01/17/2020 04:00 PM ET)
Today's Range
$2.56
Now: $2.74
$2.79
50-Day Range
$1.77
MA: $2.01
$2.74
52-Week Range
$1.43
Now: $2.74
$5.69
Volume1.46 million shs
Average Volume536,716 shs
Market Capitalization$148.52 million
P/E Ratio8.84
Dividend YieldN/A
Beta0.76
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:SBBP
CUSIPN/A
Phone610-254-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.03 million
Cash Flow$1.01 per share
Book Value$2.42 per share

Profitability

Net Income$31.85 million

Miscellaneous

Employees106
Market Cap$148.52 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive SBBP News and Ratings via Email

Sign-up to receive the latest news and ratings for SBBP and its competitors with MarketBeat's FREE daily newsletter.


5G Flaw Exposed: $5 Stock Holds Key To $12 Trillion Opportunity (Ad)


A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Strongbridge Biopharma (NASDAQ:SBBP) Frequently Asked Questions

What is Strongbridge Biopharma's stock symbol?

Strongbridge Biopharma trades on the NASDAQ under the ticker symbol "SBBP."

How were Strongbridge Biopharma's earnings last quarter?

Strongbridge Biopharma plc (NASDAQ:SBBP) announced its quarterly earnings data on Thursday, November, 7th. The biotechnology company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.32) by $0.07. The biotechnology company had revenue of $5.68 million for the quarter, compared to the consensus estimate of $5.06 million. Strongbridge Biopharma had a return on equity of 45.77% and a net margin of 211.37%. View Strongbridge Biopharma's Earnings History.

When is Strongbridge Biopharma's next earnings date?

Strongbridge Biopharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Strongbridge Biopharma.

What guidance has Strongbridge Biopharma issued on next quarter's earnings?

Strongbridge Biopharma updated its FY 2019 Pre-Market earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$18-20 million, compared to the consensus revenue estimate of $$20.82 million.

What price target have analysts set for SBBP?

5 brokerages have issued 1-year price objectives for Strongbridge Biopharma's stock. Their forecasts range from $8.00 to $18.00. On average, they expect Strongbridge Biopharma's share price to reach $13.25 in the next twelve months. This suggests a possible upside of 383.6% from the stock's current price. View Analyst Price Targets for Strongbridge Biopharma.

What is the consensus analysts' recommendation for Strongbridge Biopharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Strongbridge Biopharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Strongbridge Biopharma.

Has Strongbridge Biopharma been receiving favorable news coverage?

Media stories about SBBP stock have trended somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Strongbridge Biopharma earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Strongbridge Biopharma.

Are investors shorting Strongbridge Biopharma?

Strongbridge Biopharma saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 518,500 shares, a decrease of 19.8% from the December 15th total of 646,400 shares. Based on an average daily volume of 422,500 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the shares of the stock are sold short. View Strongbridge Biopharma's Current Options Chain.

Who are some of Strongbridge Biopharma's key competitors?

What other stocks do shareholders of Strongbridge Biopharma own?

Who are Strongbridge Biopharma's key executives?

Strongbridge Biopharma's management team includes the folowing people:
  • Mr. Matthew Pauls, CEO, Pres & Director (Age 48)
  • Mr. A. Brian Davis, Chief Financial Officer (Age 52)
  • Dr. Fredric Cohen, Chief Medical Officer (Age 54)
  • Dr. Per Marin M.D., Ph.D., Founder and Sr. Clinical Advisor
  • Mr. Peter J. Valentinsson, Sr. VP of Global Technical Operations

Who are Strongbridge Biopharma's major shareholders?

Strongbridge Biopharma's stock is owned by a number of of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.37%) and Wiley BROS. Aintree Capital LLC (0.03%). View Institutional Ownership Trends for Strongbridge Biopharma.

Which institutional investors are buying Strongbridge Biopharma stock?

SBBP stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co and Wiley BROS. Aintree Capital LLC. View Insider Buying and Selling for Strongbridge Biopharma.

How do I buy shares of Strongbridge Biopharma?

Shares of SBBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Strongbridge Biopharma's stock price today?

One share of SBBP stock can currently be purchased for approximately $2.74.

How big of a company is Strongbridge Biopharma?

Strongbridge Biopharma has a market capitalization of $148.52 million and generates $18.03 million in revenue each year. The biotechnology company earns $31.85 million in net income (profit) each year or $0.31 on an earnings per share basis. Strongbridge Biopharma employs 106 workers across the globe.View Additional Information About Strongbridge Biopharma.

What is Strongbridge Biopharma's official website?

The official website for Strongbridge Biopharma is http://www.strongbridgebio.com/.

How can I contact Strongbridge Biopharma?

Strongbridge Biopharma's mailing address is 900 NORTHBROOK DRIVE SUITE 200, TREVOSE PA, 19053. The biotechnology company can be reached via phone at 610-254-9200 or via email at [email protected]


MarketBeat Community Rating for Strongbridge Biopharma (NASDAQ SBBP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  320 (Vote Underperform)
Total Votes:  597
MarketBeat's community ratings are surveys of what our community members think about Strongbridge Biopharma and other stocks. Vote "Outperform" if you believe SBBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SBBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2020 by MarketBeat.com Staff

Featured Article: Asset Allocation

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel